Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics’ Pipeline of Next-Generation Gene Therapies to the Clinic

Partnership will include cGMP manufacturing services for AFTX-201, Affinia’s investigational gene therapy medicine for BAG3 dilated cardiomyopathy WALTHAM, Mass. and COLUMBUS, Ohio, Nov. 13, 2024 /PRNewswire/ — Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a…